摘要
Background Neuroinflammation is an immune response activated by microglia and astrocytes in the central nervous system (CNS), it is not only a result of neurodegeneration but also a crucial player in this process. the secretion of inflammatory factors in neuroinflammation mainly comes from microglia and astrocytes, and activated microglia and astrocytes are present in almost all neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases,1 The JAK/STAT signaling pathway is one of the critical factors that promote neuroinflammation in neurodegenerative diseases by initiating innate immunity, orchestrating adaptive immune mechanisms, and finally, constraining neuroinflammatory response,2 Besides, studies have suggested that Microglia release proinflammatory cytokines to cause pyroptosis through activating NLRP3 inflammasome, and the active NLRP3 inflammasome is involved in a variety of neurodegenerative diseases (Nds).3 Methods In this study, the cerebral cortices of neonatal SD rats within 1 day after birth were removed by craniotomy and primary microglia were isolated after long-term culture. IBA-1 immunofluorescence staining was used to confirm the purity of isolated microglia. Furthermore, the phosphorylation of STAT1 and STAT3 in primary rat microglia was detected by immunofluorescence method to evaluate the inhibition of the JAK/STAT pathway. In addition, the activity of NLRP3 inhibitor was evaluated by ELISA method to detect the release of cytokines in primary rat microglia. Results Our results successfully show the purity of rat primary microglia was more than 90%, and the good inhibitory effect of TYK2 inhibitor NDI-034858 on phosphorylation of STAT1 and STAT3. Moreover, ELISA assay successfully show the inhibitory effect of NLRP3 inhibitor MCC950 on IL-1β release. IC50 results of NDI-034858 and MCC950 was consistent with that in peripheral immune cells, such as lymphocytes and macrophages. Conclusions We have developed and validated various biochemical and cell-based assays to support compound screen on targets related Neuroinflammation. In sum, this study demonstrates our drug screening capabilities targeting Neuroinflammation and therefore systematically supporting new drug development in NDs. References Doty KR, Guillot-Sestier M-V, Town T. The role of the immune system in neurodegenerative disorders: adaptive or maladaptive? BRAIN Res 2015;1617:155–173. Rusek M, Smith J, El-Khatib K, Aikins K, Czuczwar SJ, Pluta R. The role of the JAK/STAT signaling pathway in the pathogenesis of alzheimer’s disease: new potential treatment target. Int J Mol Sci 2023 Jan 3;24(1):864. Yao J, Wang Z, Song W, et al. Targeting NLRP3 inflammasome for neurodegenerative disorders. Mol Psychiatry 2023;28:4512–4527. https://doi.org/10.1038/s41380-023-02239-0.